RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.
about
Patients with genetically heterogeneous synchronous colorectal cancer carry rare damaging germline mutations in immune-related genes.Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies.KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care.Whole exome sequencing reveals intertumor heterogeneity and distinct genetic origins of sporadic synchronous colorectal cancer.Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.
P2860
RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
RAS mutations vary between les ...... anti-EGFR treatment decisions.
@en
RAS mutations vary between les ...... anti-EGFR treatment decisions.
@nl
type
label
RAS mutations vary between les ...... anti-EGFR treatment decisions.
@en
RAS mutations vary between les ...... anti-EGFR treatment decisions.
@nl
prefLabel
RAS mutations vary between les ...... anti-EGFR treatment decisions.
@en
RAS mutations vary between les ...... anti-EGFR treatment decisions.
@nl
P2093
P2860
P356
P1433
P1476
RAS mutations vary between les ...... anti-EGFR treatment decisions
@en
P2093
Celso Abdon Lopes de Mello
Dirce Maria Carraro
Fernanda Machado de Melo
Isabela Werneck da Cunha
Júlia da Silva Ribeiro
Maria Dirlei Ferreira de Souza Begnami
Mariana Petaccia de Macedo
P2860
P304
P356
10.18632/ONCOSCIENCE.118
P577
2015-02-09T00:00:00Z